UK BROKER RATINGS SUMMARY: Analysts Positive On The Hut Group
UK BROKER RATINGS SUMMARY: Analysts Positive On The Hut Group
Read moreFri, 23rd Oct 2020 07:55
UK BROKER RATINGS SUMMARY: Analysts Positive On The Hut Group
Read more(Sharecast News) - Pearson: UBS upgrades to buy with a target price of 650p.
Read moreUK BROKER RATINGS SUMMARY: UBS And Barclays Raise McCarthy & Stone
Read moreLONDON BRIEFING: Buoyant Hut Group Raises Annual Revenue Guidance
Read more(Sharecast News) - Plans are being drawn up for frontline NHS staff to receive a coronavirus vaccine within weeks, as the Government moves to accelerate the timetable for a mass roll-out. An email sent by an NHS Trust chief to his staff, seen by The Mail on Sunday, reveals the Health Service is preparing for a national vaccination programme before Christmas. - Mail on Sunday
Read more(Sharecast News) - Analysts at Canaccord Genuity raised their target price on homebuilder McCarthy & Stone from 80.0p to 115.0p on Friday following today's unexpected offer from private equity group Lone Star.
Read moreTOP NEWS: McCarthy & Stone Accepts GBP630 Million Offer From Lone Star
Read moreLONDON MARKET PRE-OPEN: Barclays Quarterly Profit Up But No Payout Yet
Read moreUK BROKER RATINGS SUMMARY: Barclays Initiates Housebuilder Ratings
Read moreMcCarthy & Stone Partners With Non-Profit For Later Life Housing
Read more(Sharecast News) - Royal Dutch Shell: JP Morgan downgrades to neutral with a target price of 1,700.0p.
Read moreMcCarthy & Stone Swings To First Half Loss, Suspends Dividend
Read more(Sharecast News) - McCarthy & Stone said the impact of Covid-19 would be weighted towards the second half of the year as lower sales during the crisis drove it to a loss in the first half.
Read more(Sharecast News) - The focus in markets is likely to be on the news-flow around potential Covid-19 vaccines following confirmation that a third phase clinical trial for Moderna Therapeutics's vaccine treatment will go ahead in July as scheduled.
Read more